The New York TimesF.D.A. Approves Alzheimer's Drug Despite Fierce Debate Over Whether It Works (Published 2021)Jun 8, 2021Pam Belluck & Rebecca RobbinsBy Pam Belluck & Rebecca Robbinsmore_vert
National Institute on AgingNIA statement on FDA approval of aducanumab for Alzheimer's diseaseJun 7, 2021more_vert
STATWhy Biogen may be sitting on the most lucrative product in pharmaceutical historyJun 7, 2021Adam Feuerstein & Damian GardeBy Adam Feuerstein & Damian Gardemore_vert
FiercePharmaBiogen's shockingly broad Aduhelm label—and $56K price—set up a $10B launch, analysts sayJun 7, 2021Noah Higgins-DunnBy Noah Higgins-Dunnmore_vert
CNBCBiogen CEO says $56,000 annually for Alzheimer’s drug is 'fair,' promises not to hike price for at least 4 yearsJun 7, 2021Berkeley Lovelace & Berkeley Lovelace Jr.By Berkeley Lovelace & Berkeley Lovelace Jr.more_vert
NBC NewsFDA approves Alzheimer's drug from Biogen, against experts' adviceJun 7, 2021Sara G. MillerBy Sara G. Millermore_vert
ReutersU.S. approval of Biogen Alzheimer's drug sends shares soaring, hailed as 'big day" for patientsJun 7, 2021Julie Steenhuysen & Deena BeasleyBy Julie Steenhuysen & Deena Beasleymore_vert
Medpage TodayControversial Alzheimer's Drug Wins FDA ApprovalJun 11, 2021Judy GeorgeBy Judy Georgemore_vert
The GuardianFDA approves first new Alzheimer’s drug in almost 20 yearsJun 7, 2021Sarah BoseleyBy Sarah Boseleymore_vert
CNNIn controversial decision, FDA approves first new Alzheimer's disease drug in nearly 20 yearsJun 7, 2021Jacqueline HowardBy Jacqueline Howardmore_vert
Financial TimesAlzheimer's drug from Biogen wins US approvalJun 7, 2021Nikou AsgariBy Nikou Asgarimore_vert
ABC NewsNew Alzheimer’s drug is 1st of its kind to be FDA approvedJun 7, 2021Sony Salzman & Deepak RamanathanBy Sony Salzman & Deepak Ramanathanmore_vert
CBS NewsFDA approves Aduhelm, first new drug for Alzheimer's in 20 years, despite questionsJun 7, 2021more_vert
The New York TimesAlzheimer's Drug Poses a Dilemma for the F.D.A. (Published 2021)Oct 20, 2021Pam Belluck & Rebecca RobbinsBy Pam Belluck & Rebecca Robbinsmore_vert
The Wall Street JournalFDA Approves First New Alzheimer's Drug in Nearly Two DecadesJun 7, 2021Joseph WalkerBy Joseph Walkermore_vert
NPRAducanumab: FDA Approves Controversial Alzheimer's DrugJun 7, 2021Scott HensleyBy Scott Hensleymore_vert
CNBCBiogen shares surge 38% after FDA approves Alzheimer's drug, the first new therapy for the disease in nearly two decadesJun 7, 2021Berkeley Lovelace & Berkeley Lovelace Jr.By Berkeley Lovelace & Berkeley Lovelace Jr.more_vert
STATMember of FDA's expert panel resigns over Alzheimer's therapy approvalJun 8, 2021Andrew JosephBy Andrew Josephmore_vert
The New York TimesAlzheimer's Drug Is Bonanza for Biogen, Most Likely at Taxpayer Expense (Published 2021)Oct 20, 2021Pam Belluck & Rebecca RobbinsBy Pam Belluck & Rebecca Robbinsmore_vert
FiercePharmaBiogen's aducanumab crosses FDA finish line just in time to save its businessJun 7, 2021Noah Higgins-DunnBy Noah Higgins-Dunnmore_vert